Usama Ammar

Lecturer of Drug Discovery and Pharmaceutical Science

Edinburgh Napier University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Usama Ammar is a Lecturer of Drug Discovery and Pharmaceutical Science at Edinburgh Napier University, located in the United Kingdom. His research focuses on the design and synthesis of novel pharmaceutical compounds, with a particular interest in antimicrobial agents, kinase inhibitors, and anticancer therapies. Recent articles authored by him explore innovative chemical scaffolds and their pharmacological evaluations, contributing to advancements in drug discovery and therapeutic applications.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (5)

Andrew Paul

University Of Strathclyde

UNITED KINGDOM

View details

Robin Plevin

University Of Strathclyde

UNITED KINGDOM

View details

Mohamed A. El Hamd

SAUDI ARABIA

View details

Ahmed Elkamhawy

SOUTH KOREA

View details

Domiziana Masci

Università Cattolica del Sacro Cuore

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Usama Ammar

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Correction: Elsherbeny et al. 2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation. Life 2022, 12, 876

Design and synthesis of novel aminoindazole-pyrrolo[2,3-b]pyridine inhibitors of IKKα that selectively perturb cellular non-canonical NF-κB signalling

Discovery of Benzopyrone-Based Candidates as Potential Antimicrobial and Photochemotherapeutic Agents through Inhibition of DNA Gyrase Enzyme B: Design, Synthesis, In Vitro and In Silico Evaluation

Scaffold repurposing reveals new nanomolar phosphodiesterase type 5 (PDE5) inhibitors based on pyridopyrazinone scaffold

2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation

Structural optimization of 4-(imidazol-5-yl)pyridine derivatives affords broad-spectrum anticancer agents with selective B-RAFV600E/p38α kinase inhibitory activity

Design, synthesis, in vitro determination and molecular docking studies of 4-(1-(tert-butyl)-3-phenyl-1H-pyrazol-4-yl) pyridine derivatives with terminal sulfonamide derivatives in LPS-induced RAW264.7 macrophage cells

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening

Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors

Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor

Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600Einhibitors

Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking

Collaborators (5)

Andrew Paul

Robin Plevin

Mohamed A. El Hamd

Ahmed Elkamhawy

Domiziana Masci

Make your next move.